Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin. 2024;8(4):s406. doi:10.25251/skin.8.supp.406